Cranberry components inhibit interleukin-6, interleukin-8, and prostaglandin E2 production by lipopolysaccharide-activated gingival fibroblasts

European Journal of Oral Sciences

Volumn 115, Issue 1, 2007, Pages 64-70

  Bodet, Charles ^a   Chandad, Fatiha ^a   Grenier, Daniel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aggregatibacter actinomycetemcomitans; Anti inflammatory; Cranberry; Periodontitis; Proanthocyanidins

Indexed keywords

AUTACOID; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PLANT EXTRACT; PROANTHOCYANIDIN; PROSTAGLANDIN E2; SIGNAL PEPTIDE;

ARTICLE; CELL CULTURE; CRANBERRY; CYTOLOGY; DRUG ANTAGONISM; FIBROBLAST; GINGIVA; HUMAN; METABOLISM;

CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FIBROBLASTS; GINGIVA; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; PLANT EXTRACTS; PROANTHOCYANIDINS; VACCINIUM MACROCARPON;

EID: 33847000839     PISSN: 09098836     EISSN: 16000722     Source Type: Journal    
DOI: 10.1111/j.1600-0722.2007.00415.x     Document Type: Article

References (55)

1. OKADA H, MURAKAMI S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998; 9: 248-266.
2. BIRKEDAL-HANSEN H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993; 28: 500-510.
3. HENDERSON B, POOLE S, WILSON M. Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Microbiol Rev 1996; 60: 316-341.
4. NORSKOV-LAURITSEN N, KILIAN M. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb. nov. and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int J Syst Evol Microbiol 2006; 56: 2135-2146.
5. SLOTS J, LISTGARTEN MA. Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases. J Clin Periodontol 1988; 15: 85-93.
6. HENDERSON B, WILSON M, SHARP L, WARD JM. Actinobacillus actinomycetemcomitans. J Med Microbiol 2002; 51: 1013-1020.
7. 2 and interleukin-1 alpha in the differentiation and survival of osteoclasts induced by lipopolysaccharide from Actinobacillus actinomycetemcomitans Y4. J Periodontal Res 1998; 33: 509-516.
8. TIRANATHANAGUL S, YONGCHAITRAKUL T, PATTAMAPUN K, PAVASANT P. Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. J Periodontol 2004; 75: 1647-1654.
9. WANG PL, Ohura K, FUJII T, OIDO- MORI M, KOWASHI Y, KIKUCHI M, SUETSUGU Y, TANAKA J. DNA microarray analysis of human gingival fibroblasts from healthy and inflammatory gingival tissues. Biochem Biophys Res Commun 2003; 305: 970-973.
10. TAKASHIBA S, NARUISHI K, MURAYAMA Y. Perspective of cytokine regulation for periodontal treatment: fibroblast biology. J Periodontol 2003; 74: 103-110.
11. PAQUETTE DW, WILLIAMS RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000 2000; 24: 239-252.
12. REED J. Cranberry flavonoids, atherosclerosis and cardiovascular health. Crit Rev Food Sci Nutr 2002; 42: 301-316.
13. RAZ R, CHAZAN B, DAN M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004; 38: 1413-1419.
14. FERGUSON PJ, KUROWSKA E, FREEMAN DJ, CHAMBERS AF, KOROPATNICK DJ. A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr 2004; 134: 1529-1535.
15. BODET C, CHANDAD F, GRENIER D. Anti-inflammatory activity of a high-molecular-weight cranberry fraction on macrophages stimulated by lipopolysaccharides from periodontopathogens. J Dent Res 2006; 85: 235-239.
16. DARVEAU RP, HANCOCK RE. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 1983; 155: 831-838.
17. 2 secretion as a determinant of periodontal disease expression. J Periodontol 1993; 64: 432-444.
18. GOODSON JM, DEWHIRST FE, BRUNETTI A. Prostaglandin E2 levels and human periodontal disease. Prostaglandins 1974; 6: 81-85.
19. MORTON RS, DONGARI-BAGTZOGLOU AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001; 72: 461-469.
20. 2 and alkaline phosphatase in gingival crevicular fluid: their relations to periodontal status. J Clin Periodontol 1994; 21: 327-333.
21. RICHARDS D, RUTHERFORD RB. The effects of interleukin 1 on collagenolytic activity and prostaglandin-E secretion by human periodontal-ligament and gingival fibroblast. Arch Oral Biol 1988; 33: 237-243.
22. STEFFEN MJ, HOLT SC, EBERSOLE JL. Porphyromonas gingivalis induction of mediator and cytokine secretion by human gingival fibroblasts. Oral Microbiol Immunol 2000; 15: 172-180.
23. NOGUCHI K, SHITASHIGE M, YANAI M, MORITA I, NISHIHARA T, MUROTA S, ISHIKAWA I. Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides. Inflammation 1996; 20: 555-568.
24. REDDY MS, GEURS NC, GUNSOLLEY JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003; 8: 12-37.
25. MATHUR A, MICHALOWICZ B, CASTILLO M, AEPPLI D. Interleukin-1 alpha, interleukin-8 and interferon-alpha levels in gingival crevicular fluid. J Periodontal Res 1996; 31: 489-495.
26. TSAI CC, HO YP, CHEN CC. Levels of interleukin-1 beta and interleukin-8 in gingival crevicular fluids in adult periodontitis. J Periodontol 1995; 66: 852-859.
27. JIN LJ, LEUNG WK, CORBET EF, SODER B. Relationship of changes in interleukin-8 levels and granulocyte elastase activity in gingival crevicular fluid to subgingival periodontopathogens following non-surgical periodontal therapy in subjects with chronic periodontitis. J Clin Periodontol 2002; 29: 604-614.
28. GAMONAL J, ACEVEDO A, BASCONES A, JORGE O, SILVA A. Characterization of cellular infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES chemokines in adult periodontitis. J Periodontal Res 2001; 36: 194-203.
29. DONGARI-BAGTZOGLOU AI, EBERSOLE JL. Increased presence of interleukin-6 (IL-6) and IL-8 secreting fibroblast subpopulations in adult periodontitis. J Periodontol 1998; 69: 899-910.
30. IRWIN CR, MYRILLAS TT. The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis 1998; 4: 43-47.
31. TAKAHASHI K, TAKASHIBA S, NAGAI A, TAKIGAWA M, MYOUKAI F, KURIHARA H, MURAYAMA Y. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontol 1994; 65: 147-153.
32. KENT LW, RAHEMTULLA F, MICHALEK SM. Interleukin (IL)-1 and Porphyromonas gingivalis lipopolysaccharide stimulation of IL-6 production by fibroblasts derived from healthy or periodontally diseased human gingival tissue. J Periodontol 1999; 70: 274-282.
33. ISHIMI Y, MIYAURA C, JIN CH, AKATSU T, Abe E, NAKAMURA Y, YAMAGUCHI A, YOSHIKI S, MATSUDA T, HIRANO T. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297-3303.
34. KURIHARA N, BERTOLINI D, SUDA T, AKIYAMA Y, ROODMAN GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144: 4226-4230.
35. YAMAGUCHI K, LANTOWSKI A, DANNENBERG AJ, SUBBARAMAIAH K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 2005; 280: 32569-32577.
36. 2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 2005; 29: 159-168.
37. MUKAIDA N, OKAMOTO S, ISHIKAWA Y, MATSUSHIMA K. Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 1994; 56: 554-558.
38. MORSE D, PISCHKE SE, ZHOU Z, DAVIS RJ, FLAVELL RA, LOOP T, OTTERBEIN SL, OTTERBEIN LE, CHOI AM. Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1. J Biol Chem 2003; 278: 36993-36998.
39. WANG PL, OHURA K. Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts-CD14 and Toll-like receptors. Crit Rev Oral Biol Med 2002; 13: 132-142.
40. MINDEN A, KARIN M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997; 1333: F85-F104.
41. SMEAL T, ANGEL P, MEEK J, KARIN M. Different requirements for formation of Jun:Jun and Jun:Fos complexes. Genes Dev 1989; 3: 2091-2100.
42. INOUE T, HAMMAKER D, BOYLE DL, FIRESTEIN GS. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol 2005; 174: 4301-4306.
43. SANLIOGLU S, WILLIAMS CM, SAMAVATI L, BUTLER NS, WANG G, MCCRAY PB Jr, RITCHIE TC, HUNNINGHAKE GW, ZANDI E, ENGELHARDT JF. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem 2001; 276: 30188-30198.
44. CHERLA RP, LEE SY, MEES PL, TESH VL. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J Leukoc Biol 2006; 79: 397-407.
45. BUXADE M, PARRA JL, ROUSSEAU S, SHPIRO N, MARQUEZ R, MORRICE N, BAIN J, ESPEL E, PROUD CG. The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 2005; 23: 177-189.
46. PAQUAY JB, HAENEN GR, STENDER G, WISEMAN SA, TIJBURG LB, BAST A. Protection against nitric oxide toxicity by tea. J Agric Food Chem 2000; 48: 5768-5772.
47. SINHA D, ROY M, DEY S, SIDDIQI M, BHATTACHARYA RK. Modulation of arsenic induced cytotoxicity by tea. Asian Pac J Cancer Prev 2003; 4: 233-237.
48. MIYAGAWA C, WU C, KENNEDY DO, NAKATANI T, OHTANI K, SAKANAKA S, KIM M, MATSUI-YUASA I. Protective effect of green tea extract and tea polyphenols against the cytotoxicity of 1,4-naphthoquinone in isolated rat hepatocytes. Biosci Biotechnol Biochem 1997; 61: 1901-1905.
49. BERNHARD D, SCHWAIGER W, CRAZZOLARA R, TINHOFER I, KOFLER R, CSORDAS A. Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells. Cancer Lett 2003; 195: 193-199.
50. KORNMAN KS. Host modulation as a therapeutic strategy in the treatment of periodontal disease. Clin Infect Dis 1999; 28: 520-526.
51. STEINBERG D, FELDMAN M, OFEK I, WEISS EI. Effect of a highmolecular-weight component of cranberry on constituents of dental biofilm. J Antimicrob Chemother 2004; 54: 86-89.
52. YAMANAKA A, KIMIZUKA R, KATO T, OKUDA K. Inhibitory effects of cranberry juice on attachment of oral streptococci and biofilm formation. Oral Microbiol Immunol 2004; 19: 150-154.
53. WEISS EI, KOZLOVSKY A, STEINBERG D, LEV-DOR R, BAR NESS GREENSTEIN R, FELDMAN M, SHARON N, OFEK I. A high molecular mass cranberry constituent reduces mutans streptococci level in saliva and inhibits in vitro adhesion to hydroxyapatite. FEMS Microbiol Lett 2004; 232: 89-92.
54. LABRECQUE J, BODET C, CHANDAD F, GRENIER D. Effects of a high-molecular-weight cranberry fraction on growth, biofilm formation and adherence of Porphyromonas gingivalis. J Antimicrob Chemother 2006; 58: 439-443.
55. BODET C, CHANDAD F, GRENIER D. Inhibition of extracellular matrix destructive enzyme production and activity by cranberry compounds. J Periodontal Res 2006; in press.